Kosan Biosciences has initiated a Phase I multicenter trial of an oral formulation of KOS-1022 (DMAG), a second-generation heat shock protein 90 (Hsp90) inhibitor. KOS-1022 is the first-reported Hsp90 ...
Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors
Laboratory for Food and Medicine Homologous Natural Resources Development and Utilization, Dezhou University, Dezhou City 253023, Shandong Province, China ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
In addition, organoids with high Eif5a2 expression were shown to be sensitive to AKT inhibitors. As a final step, the team analysed two databases of human prostate cancer samples, which confirmed a ...
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...
a) Bioactive screen results with select inhibitors grouped and uniquely colored by pathway. Change in f bound across a 12-pt dose titration of three representative compounds targeting each of HSP90, ...
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
It has pursued the discovery and development of HSP90 inhibitors, as one way of preventing or overcoming drug resistance. The division is also interested in ways of planning drug regimens or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback